BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21627385)

  • 1. SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated.
    Qiu H; Zhu J; Yu J; Pu H; Dong R
    Asian Pac J Cancer Prev; 2011; 12(3):791-5. PubMed ID: 21627385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent epigenetic inactivation of the SLIT2 gene in gliomas.
    Dallol A; Krex D; Hesson L; Eng C; Maher ER; Latif F
    Oncogene; 2003 Jul; 22(29):4611-6. PubMed ID: 12881718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells.
    Dallol A; Morton D; Maher ER; Latif F
    Cancer Res; 2003 Mar; 63(5):1054-8. PubMed ID: 12615722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas.
    Jin J; You H; Yu B; Deng Y; Tang N; Yao G; Shu H; Yang S; Qin W
    Biochem Biophys Res Commun; 2009 Jan; 379(1):86-91. PubMed ID: 19100240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
    Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
    Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer.
    Dong R; Yu J; Pu H; Zhang Z; Xu X
    J Int Med Res; 2012; 40(2):681-6. PubMed ID: 22613430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
    Alvarez C; Tapia T; Cornejo V; Fernandez W; Muñoz A; Camus M; Alvarez M; Devoto L; Carvallo P
    Mol Carcinog; 2013 Jun; 52(6):475-87. PubMed ID: 22315090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
    Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
    Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.
    Yang H; Das P; Yu Y; Mao W; Wang Y; Baggerly K; Wang Y; Marquez RT; Bedi A; Liu J; Fishman D; Lu Z; Bast RC
    Oncotarget; 2016 Jan; 7(3):3018-32. PubMed ID: 26689988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
    Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients.
    Kim GE; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
    Virchows Arch; 2011 Oct; 459(4):383-90. PubMed ID: 21894562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation of SLIT2 is a risk factor and potential diagnostic biomarker for nasopharyngeal carcinoma.
    Li J; Zhou C; Wang G; Wang S; Ni S; Ye M; Zhang J
    Gene; 2018 Feb; 644():74-79. PubMed ID: 29107007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer.
    Yanaihara N; Nishioka M; Kohno T; Otsuka A; Okamoto A; Ochiai K; Tanaka T; Yokota J
    Int J Cancer; 2004 Oct; 112(1):150-4. PubMed ID: 15305387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene.
    Singh RK; Indra D; Mitra S; Mondal RK; Basu PS; Roy A; Roychowdhury S; Panda CK
    Hum Genet; 2007 Aug; 122(1):71-81. PubMed ID: 17609981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
    J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
    Meng CF; Dai DQ; Guo KJ
    Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis.
    Tseng RC; Lee SH; Hsu HS; Chen BH; Tsai WC; Tzao C; Wang YC
    Cancer Res; 2010 Jan; 70(2):543-51. PubMed ID: 20068157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.